Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?
Cancer Medicine · 2025
DOI: 10.1002/cam4.71119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Michal Eid und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Lékařská fakulta, Masarykova univerzita, Ministerstvo Školství, Mládeže a Tělovýchovy.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Molecular tumor boards (MTBs) support the development of personalized treatment strategies for patients with various cancer types based on comprehensive genomic profiling (CGP) of tumor tissue. Despite the unprecedented results demonstrated in many molecularly driven clinical trials, access to matched therapy remains a significant challenge in routine clinical practice worldwide.
Methods
In this study, we analyzed the MTB cohort from University Hospital Brno in the Czech Republic. Between February 2021 and April 2025, a total of 553 cancer patients with limited therapeutic options underwent CGP of tumor tissue and were subsequently presented at the MTB.
Results
The median age of the patients was 61.1 years, and 62.2% were female. The most frequently tested diagnoses were colorectal cancer ( n = 88; 15.9%), cholangiocarcinoma ( n = 66; 11.9%), and pancreatic cancer ( n = 65; 11.8%). The median number of prior lines of standard systemic therapy before CGP testing was two. MTB‐recommended matched therapy for 326 (59.0%) out of 553 tested patients, based on 545 unique molecular alterations. The most frequently recommended drugs included immunotherapy (162/545; 29.7%), tyrosine kinase inhibitors (140/545; 25.7%), and poly (ADP‐ribose) polymerase inhibitors (63/545; 11.6%). Reimbursement was requested from healthcare insurance providers in 115 cases, with 87 (75.7%) approvals. Together with other reimbursement forms, a total of 96 (17.4%) out of 553 patients initiated matched therapy. A progression‐free survival ratio (PFS2/PFS1) of ≥ 1.3 was observed in 29 (41.4%) of the 70 evaluable pretreated patients.
Conclusion
This is the first study to report on a real‐world MTB cohort from the Czech Republic, demonstrating a diagnostic yield comparable to previously published studies, good availability of recommended drugs, and clinical benefit in evaluable patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Center for Precision Medicine, University Hospital Brno, Brno, Czech Republic.
- Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Respiratory Diseases, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Radiology and Nuclear Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
ORCID-Profile: Michal Eid, Markéta Bednaříková, Jakub Trizuljak, Štěpán Tuček, Monika Bratová, Tomáš Rohan, Zdeněk Kala, Zdeněk Král, Jiří Mayer, Ondřej Slabý
Förderung
- European Union
- Lékařská fakulta, Masarykova univerzita
- Ministerstvo Školství, Mládeže a Tělovýchovy
- Ministry of Health
- European Commission
Zitieren
APA
Eid, M., Bednaříková, M., Vlažný, J., Hausnerová, J., Taslerová, R., Vilmanová, S., Jelínková, M., Homolová, A., Gryc, M., Trizuljak, J., Pavlovský, Z., Tuček, Š., Brančíková, D., Bratová, M., Rohan, T., Kala, Z., Král, Z., Mayer, J., Svobodník, A., & Slabý, O. (2025). Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?. Cancer Medicine. https://doi.org/10.1002/cam4.71119
Vancouver
Eid M, Bednaříková M, Vlažný J, Hausnerová J, Taslerová R, Vilmanová S, et al. Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?. Cancer Medicine. 2025. doi:10.1002/cam4.71119
BibTeX
@article{Eid2025,
author = {Eid, Michal and Bednaříková, Markéta and Vlažný, Jakub and Hausnerová, Jitka and Taslerová, Renata and Vilmanová, Sára and Jelínková, Martina and Homolová, Alena and Gryc, Martin and Trizuljak, Jakub and Pavlovský, Zdeněk and Tuček, Štěpán and Brančíková, Dagmar and Bratová, Monika and Rohan, Tomáš and Kala, Zdeněk and Král, Zdeněk and Mayer, Jiří and Svobodník, Adam and Slabý, Ondřej},
title = {Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71119}
}
EUVIMED